首页> 外文期刊>Diabetes, obesity & metabolism >Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
【24h】

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme

机译:每周达拉蛋白质对奖励计划中2型糖尿病的基线β细胞功能的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide‐treated patients from AWARD‐1, AWARD‐3 and AWARD‐6 clinical studies were categorised based on their homeostatic model assessment of beta‐cell function (HOMA2‐%B) tertiles. Changes in glycaemic measures in response to treatment with once‐weekly dulaglutide were evaluated in each HOMA2‐%B tertile. Patients with low HOMA2‐%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes ( P ??.001, all) (mean low, middle and high tertiles with dulaglutide 1.5?mg: HOMAB‐2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26?weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5?mg (mean; ?1.55% vs. ?0.98% [?16.94 vs. ?10.71?mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; ?1.00 vs. ?1.18% [?10.93 vs. ?12.90?mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C‐peptide were observed in the low tertile. Similar increases in HOMA2‐%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta‐cell function.
机译:胰高血糖素的肽-1受体激动剂部分通过葡萄糖依赖性胰岛素分泌刺激的2型糖尿病(T2D)中的血糖降低血糖。本研究的目的是探讨基线上β细胞功能(如HOMA2-%B)是否会影响杜拉格兰蛋白质的血糖反应。根据β细胞功能(HOMA2-%B)型号的稳态模型评估,对奖金-1和奖励-6临床研究的杜拉替金属治疗患者进行分类。在每个HOMA2%B Tertile中评估促次达尔蛋白质治疗的血糖措施的变化。 HOMA2-%B低的患者具有更高的基线糖化血红蛋白(HBA1C),禁食和餐后血糖,以及较长的糖尿病持续时间(P?001,全部)(平均低,中间和杜拉格兰蛋白质的高型乳房1.5? Mg:Homab-2%B,31%,58%,109%; HBA1C,8.7%,7.7%,7.3%)。在26个?周,与杜拉蛋白蛋白剂的高触感相比,低间隙在HBA1C中较大减少(平均值;?1.55%与α.0.98%[α16.94与Δ10.71?mmol / mol])。当为基线HBA1C调整时,低间隙和高效率之间的差异(LSM;?1.00与α1.18%[α1.1.10.93vs.1.12.90?mmol / mol])消失。在低间隙中观察到禁食血糖中更大的血糖减小,并且在低间隙中观察到禁食C-肽的增加。在所有截头都观察到HOMA2-%B类似的增加。杜拉格拉特德在临床上表现出相关的HBA1C,无论估计的基线β细胞功能如何。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号